NEW YORK, November 9, 2016 /PRNewswire/ --
Pre-market, Stock-Callers.com redirects its focus on CVS Health Corp.(NYSE: CVS), Express Scripts Holding Co. (NASDAQ: ESRX), UnitedHealth Group Inc. (NYSE: UNH), and Lipocine Inc. (NASDAQ: LPCN). These companies belong to the Healthcare sector which ended higher for a third day in a row on Tuesday,
Woonsocket, Rhode Island headquartered CVS Health Corp.'s stock finished Tuesday's session 11.82% lower at $73.53. A total volume of 50.23 million shares was traded, which was above their three months average volume of 5.64 million shares. The Company's shares are trading below their 50-day moving average by 16.66%. Furthermore, shares of CVS Health, which together with its subsidiaries, provides integrated pharmacy health care services, have a Relative Strength Index (RSI) of 21.42.
On November 08th, 2016, CVS Health reported that net revenues for Q3 2016 increased 15.5%, or $6.0 billion, to $44.6 billion compared to Q3 2015. The company's net income for the reported quarter was $1.5 billion, an increase of $294 million, or 23.6% from the prior year quarter. Cash flow from operations was $7.9 billion on an YTD basis. The free report on CVS is available at
On Tuesday, shares in St. Louis, Missouri headquartered Express Scripts Holding Co. ended the session at $69.85, down 0.75%. The stock recorded a trading volume of 5.76 million shares, which was higher than its three months average volume of 3.71 million shares. The Company's shares are trading 0.60% below their 50-day moving average. Moreover, shares of Express Scripts Holding, which operates as a pharmacy benefit management (PBM) company in the US, Canada, and Europe, have an RSI of 51.25.
On November 03rd, 2016, Express Scripts announced that Express Scripts Medicare® Prescription Drug Plan (PDP), contract S5660, has once again earned a 4-Star* quality rating from the Centers for Medicare and Medicaid Services (CMS). Express Scripts 2017 Medicare Value and Choice plans offer additional cost savings through a preferred pharmacy network - which includes more than 8,200 Walgreens pharmacies nationwide and more than 21,000 independent pharmacies - and Express Scripts Home Delivery Pharmacy.
On November 04th, 2016, research firm Deutsche Bank upgraded the Company's stock rating from 'Sell' to 'Hold'. The research firm also revised upwards its previous target price from $69 to $70. The complimentary report on ESRX can be downloaded at:
Minnetonka, Minnesota-based UnitedHealth Group Inc.'s stock ended yesterday's session 0.68% higher at $142.90. A total volume of 4.33 million shares was traded, which was above their three months average volume of 3.17 million shares. The Company's shares have advanced 3.49% in the past month, 0.96% in the previous three months, and 23.09% on an YTD basis. The stock is trading 3.28% above its 50-day moving average and 7.91% above its 200-day moving average. Additionally, shares of UnitedHealth Group, which operates as a diversified health and well-being company in the US, have an RSI of 58.99.
On October 19th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $160 a share to $169 a share.
On November 01st, 2016, Insperity, Inc. announced an amendment to its contract for medical coverage with UnitedHealthcare, a UnitedHealth Group. This amendment allows for this successful 15-year relationship to continue the ongoing commitment of both companies to focus on controlling health care costs. Visit us today and download our complete research report on UNH for free at:
At the close on Tuesday, shares in Salt Lake City, Utah headquartered Lipocine Inc. recorded a trading volume of 212,838 shares. The stock finished 8.47% higher at $3.33. The Company's shares are trading below their 50-day moving average by 11.41%. Furthermore, shares of Lipocine, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have an RSI of 44.28.
On November 08th, 2016, Lipocine reported a net loss of $3.2 million, or $0.18 per diluted share, for Q3 2016 compared to a net loss of $6.4 million, or $0.35 per diluted share, for Q3 2015. For the reported quarter, research and development expenses were $1.5 million compared to $4.7 million for Q3 2015. The change was primarily due to decreased contract research organization and consultant costs as well as a $2.3 million fee paid in 2015 to file its NDA for LPCN 1021 with the FDA. As of September 30th, 2016, Lipocine had cash, cash equivalents, and marketable investment securities of $28.8 million. Get free access to your technical report on LPCN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All